anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to the field of medical devices and discloses a program control system and method for an implantable electronic device. The program control system includes at least one communication device, at least one terminal device and a cloud server communicatively connected to both the communication device and the terminal device. The communication device is configured to acquire feedback data from the implantable electronic device (IED) and upload the feedback data to the cloud server. The cloud server is configured to process the feedback data and store the processed feedback data. The terminal device is configured to retrieve the processed feedback data from the cloud server for enquiry by a user. In the present invention, there is also provided a program control method for an implantable electronic device. The present invention entails a processing mode for use on a cloud platform in which individual components in the program control system can be separately upgraded in a timely manner, thus lowering the hardware upgrading cost and achieving more scientific analysis and management of data.
Cerebral small vessel disease is the one of the most prevalent causes of vascular cognitive impairment. We aimed to find objective and process-based indicators related to memory function to assist in the detection of memory impairment in patients with cerebral small vessel disease. Thirty-nine cerebral small vessel disease patients and 22 healthy controls were invited to complete neurological examinations, neuropsychological assessments, and eye tracking tasks. Eye tracking indicators were recorded and analyzed in combination with imaging features. The cerebral small vessel disease patients scored lower on traditional memory task and performed worse on eye tracking memory task performance compared to the healthy controls. The cerebral small vessel disease patients exhibited longer visit duration and more visit count within areas of interest and targets and decreased percentage value of total visit duration on target images to total visit duration on areas of interest during decoding stage among all levels. Our results demonstrated the cerebral small vessel disease patients performed worse in memory scale and eye tracking memory task, potentially due to their heightened attentional allocation to nontarget images during the retrieval stage. The eye tracking memory task could provide process-based indicators to be a beneficial complement to memory assessment and new insights into mechanism of memory impairment in cerebral small vessel disease patients.
During intensive care unit admission, relatives of critically ill patients can experience emotional distress. The authors hypothesized that families of patients who are diagnosed with intensive care unit (ICU) delirium experience more profound depression and anxiety disorders related to stress than do families of patients without delirium. We performed a prospective observational single-center study including families of adult patients (age above 18 years) hospitalized in a 17-bed ICU of a university hospital for at least 48 h who completed research questionnaires at day 2 after admission and day 30 after initial evaluation using dedicated questionnaires (HADS, CECS, IES, PTSD-C). A total of 98 family members of patients hospitalized in the ICU were included in the final analysis (50 family members whose relatives were CAM-ICU positive (DEL+), and 48 family members of patients without delirium (DEL-)). No statistically significant differences in demographics and psychosocial data were found between the groups. In the follow-up 30 days after the first conversation with a family member, the mean PTSD score for the relatives of patients with delirium was 11.02 (Me = 13.0; SD = 5.74), and the mean score for nondelirious patients' family members was 6.42 (Me = 5.5; SD = 5.50; p < 0.001). A statistically significant increase in IES scores for family members of patients with delirium was observed for total PTSD (p = 0.001), IES-intrusion (p < 0.001), and IES-hyperarousal (p = 0.002). The prevalence of anxiety symptoms, depression, and posttraumatic stress disorder (PTSD) was higher in families of patients diagnosed with ICU delirium within 48 h of admission to the ICU. No factors increasing the depth of these disorders in family members of patients with ICU delirium were identified. Taking appropriate actions and thus providing families with appropriate support will contribute to the understanding of unfavorable emotional states, including anxiety, stress, depression, anger, agitation, or avoidance.
FIELD: medicine. SUBSTANCE: method involves introducing a medicinal preparation into organism. The medicinal preparation is produced as 0.1% solution of estradiol benzoate and estradiol propionate in oil at a dose of 20000-60000 active units in combination with sulfate. It is administered slowly into the right inguinal lymphatic node during 10 min with preparatory infiltration anesthesia. The preparation can be administered as a single dose depending on uterine neck maturity and uterus readiness to labor with medical preparations application. EFFECT: enhanced effectiveness of the method. 4 cl
This study uses a varied 3 + 3 design. Three patients will be started at a dose of 10 mg/m\^2 days 1, 3 and 5. If no DLTs are observed in the first 3 participants, then a new cohort will be enrolled at the next planned dose level of 15 mg/m\^2 days 1, 3 and 5. If two out of three subjects experience a DLT, then they will de-escalate one dose level. If one subject in three experiences a DLT, then expand up to three subjects at 20 mg/m\^2 day 1, 3 and 5. If two out of six subjects experience a DLT, de-escalate one level. All subjects will receive Azacitidine and Venetoclax at the indicated dosages and timing.
In this arm, pediatric clinics are randomized to receive access for their parents and practitioners to a referral website designed to assist parents of children with disruptive behavior disorders in accessing appropriate community resources; on the website, community resources for treatment of child disruptive behavior disorders (mental health services, parenting services) are described and can be searched by location, cost, and acceptance of Medicare. Parents in this condition receive access to the Triple P Online System (TPOS) after completion of their 1-year follow-up assessment. Pediatricians receive free training in TPOS at the end of their waiting period.
Hypersensitivity to any component of this medication.

Active liver disease or unexplained persistent elevations of serum transaminases (see WARNINGS). 

Concomitant administration with strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, HIV protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin, nefazodone, and cobicistat-containing products) (see WARNINGS, Myopathy/Rhabdomyolysis). 

Pregnancy and lactation (see PRECAUTIONS, Pregnancy and Nursing Mothers).

Atherosclerosis is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia. Moreover, cholesterol and other products of the cholesterol biosynthesis pathway are essential components for fetal development, including synthesis of steroids and cell membranes. Because of the ability of inhibitors of HMG-CoA reductase such as lovastatin to decrease the synthesis of cholesterol and possibly other products of the cholesterol biosynthesis pathway, lovastatin is contraindicated during pregnancy and in nursing mothers. Lovastatin should be administered to women of childbearing age only when such patients are highly unlikely to conceive. If the patient becomes pregnant while taking this drug, lovastatin should be discontinued immediately and the patient should be apprised of the potential hazard to the fetus (see PRECAUTIONS, Pregnancy).
PURPOSE:To industrially advantageously obtain the subject formulation useful for stenocardia, etc., having excellent stability by a favorable method by dissolving a specific amount of nifedipine and a water-soluble polymer in an organic solvent, adding a specific amount of water-insoluble polymer and pelletizing by a wet method. CONSTITUTION:1 pt.wt. nifedipine and 0.5-3.0 pts.wt. water-soluble polymer are dissolved in an organic solvent (e.g. chloroform, dichloromethane or carbon tetrachloride) and 3.0-10.0 pts.wt. water-insoluble polymer is added, then the resultant solution is pelletized by a wet method to afford the objective nifedipine solid formulation. One, two or more of polyvinylpyrrolidone, hydroxypropyl cellulose and hydroxypropyl methylcellulose are used as the water-soluble polymer. Furthermore, crystalline cellulose is used as water-insoluble polymer.
INTRODUCTION: Effective rehabilitation after total knee arthroplasty (TKA) and unicompartmental knee arthroplasty (UKA) is often impeded by pain and swelling. Beneficial short-term effects in terms of pain and opioid use after a short period of cryotherapy (±compression therapy) have been demonstrated. The effectiveness of a longer intervention period on longer-term postoperative outcomes is unclear. This study aims to assess the effects of 6 weeks of cryotherapy plus compression therapy on pain, functioning and patient satisfaction after TKA or UKA.
METHODS AND ANALYSIS: A single-centre, single-blind randomised controlled trial will be conducted at a teaching hospital in the Netherlands. Patients over age 18 with end-stage osteoarthritis planned for a TKA or UKA are eligible; 104 UKA and 104 TKA patients will be included. Both groups will be randomly allocated (1:1) into an intervention group receiving 6 weeks of cryotherapy plus compression therapy (commencing after discharge from hospital) or a control group (usual care). The primary endpoint is perceived pain at rest at 6 weeks postoperatively. Secondary outcomes include compliance with cold protocol, pain at rest during the first six postoperative weeks and at 6 and 12 months postoperatively, pain on weight bearing, opioid use, functioning, patient satisfaction and complications.
ETHICS AND DISSEMINATION: The local medical ethics committee MEC-U approved the study protocol (R22.095/NL-number NL81956.100.22). The study will be conducted in accordance with the Declaration of Helsinki and Good Clinical Practice regulations, and personal data will be handled in agreement with the Dutch Personal Data Protection Act (AGV). Written informed consent will be obtained prior to performing any of the study procedures. We will disseminate study results through multiple peer-reviewed publications and through conference presentations.
TRIAL REGISTRATION NUMBER: NCT05572359.
BACKGROUND: Mechanical cardiac support is currently an effective strategy to reduce morbidity and mortality in pediatric patients. However, solid evidence regarding the feasibility of intracorporeal devices in children still needs to be provided. We report our 10-year experience with intracorporeal left ventricular assist devices (LVAD) in children.
MATERIALS AND METHODS: We included all patients undergoing intracorporeal, continuous-flow LVAD implantation between 2012 and 2022. Baseline and postoperative data were collected from the institutional database.
RESULTS: Seven HeartWare and 4 HeartMate3 were implanted in 11 patients (median age 13.9 years, median body surface area - BSA - 1.42 m2, IQR 1.06-1.68). The most frequent indication to LVAD implant was dilated cardiomyopathy (72.7%). All candidates underwent a thorough preoperative advanced imaging. Three-dimensional reconstructions and implant fit simulation were performed when BSA was <1.2 m2, weight <30 kg, or internal transverse thoracic diameter <20 cm. There was no operative death. The most common postoperative complication was surgical re-exploration due to bleeding (27.3%). One patient died of severe neurological complications after about 3 months of hospitalization. No late deaths or unplanned re-hospitalizations occurred in the remaining 10, 6 of whom were discharged home. There were no major complications at the follow-up. All survivors underwent successful heart transplantation.
CONCLUSIONS: Intracorporeal LVAD implantation proved to be a potentially feasible and safe option in young teenagers and children whose BSA was >1.0 m2. In borderline cases, the 3D reconstruction with implant fit simulation can effectively help to identify those patients who can safely undergo intrathoracic LVAD implantation.
The aim of this study is to determine of the effects of supplementation with n-3 fatty acid or placebo for 10 weeks on the expression of Sirt-1, AdipoR1(adiponectin receptor 1) \& AdipoR2 (adiponectin receptor 2) genes in the peripheral blood mononuclear cell (PBMC) and circulatory levels of Resistin, MCP-1 (Monocyte Chemoattractant Protein-1) and Adiponectin of type2 diabetes patient. In this randomized, double-blind clinical trial, placebo-controlled, 88 men and women with type 2 diabetes are enrolled in the study from the Iranian Diabetes Association. After signing informed consent all individuals complete a general information form , 24-hour food recall for 3 days and beck depression questionnaire will be taken from the participants at the beginning and the end of the study. Selected samples are randomly classified into 2 blocks of groups receiving supplement and placebo. The supplement group, will receive mg 1800mg EPA(Eicosapentaenoic acid ) \& 900mg DHA( docosahexaenoic acid) (total=2700mg) for 10 weeks and the placebo group will also receive placebo (containing 2700 mg of edible paraffin) (similar in terms of color, shape and size). Patients are recommended to sustain their diets and medication dose (s) during the study and also advised to maintain a constant level of physical activity. Blood samples will be collected after 12 hours fasting and anthropometric variables, biochemical parameters, target gene expression and physical activity before and after the trial will be measured
ETHNOPHARMACOLOGICAL RELEVANCE: Corchorus olitorius is used in ethnomedicine to arrest threatened miscarriage, ease labour, and promote smooth childbirth.
AIM OF THE STUDY: To evaluate the phytochemical composition, toxicity profile, and effect of Corchorus olitorius L. leaf extract (COLE) on fetal macrosomia control in rats.
MATERIALS AND METHODS: The chemical constituents of COLE were determined using gas chromatography-mass spectrometry (GC-MS). A single dose of up to 5000 mg/kg was administered in the acute toxicity test, and the rats were monitored for 14 days. In the sub-acute toxicity study, rats were treated with the extract for 28 days, and liver function, renal function, lipid profile, and serum antioxidant parameters, coupled with liver and kidney histology, were used to assess the toxicity potential of the extract. In the pup birth weight study, treatment of pregnant rats lasted until the birth of pups and continued for an extra 4 weeks. Rats in group 1 served as a control, whereas rats in groups 2, 3, and 4 received daily doses of 200, 400, and 800 mg/kg body weight of COLE, respectively, via oral gavage.
RESULTS: Bioactive compounds such as D-limonene, phytol, hexadecanoic acid, 9-octadecenoic acid (Z), dodecanoic acid, and ethyl 9,12,15-octadecatrienoate with well-known pharmacological activities were detected. LD50 of COLE was >5000 mg/kg. COLE decreased body weight and increased red blood cell, packed cell volume, and haemoglobin values when compared with the control (p < 0.05). COLE significantly decreased alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase but did not cause any significant (p > 0.05) changes in other biochemical (liver and kidney) parameters when compared to control. COLE decreased total cholesterol, triglycerides, low-density lipoprotein cholesterol, and increased high-density lipoprotein cholesterol when compared with the control (p < 0.05). Birth weights of pups were significantly decreased in the COLE-treated groups when compared with the control (p < 0.05), but the observed difference terminated by the fourth week of weaning.
CONCLUSION: The results showed that COLE is not toxic but has several bioactive compounds with known pharmacological activities and therefore may be a safe oral agent for fetal macrosomia control.
An event reporting program (48) is provided which electronically records information critical to reconstructing events occurring during an emergency incident. The event reporting program (48) includes an event recording component (204) for recording events as they occur during the incident, and a post-processing component (206) for further processing the events recorded by the event recording component after completion of the incident. The event recording component (204) enables an emergency service provider to input a plurality of event records (148) describing each event as it occurs and the time at which each event takes place. The event recording component also enables an emergency service provider to input a predefined protocol of expected event records. Each expected event record (148) identifies an event which is expected to occur during the incident and a time at which the event is expect to occur. Finally, the event recording component also includes a number of tools for providing and/or recording information in addition to the event records to the emergency service provider, e.g., an address book, drug guidelines, a narrative recorder, etc. The post-processing component (206), on the other hand, enables the user to modify or add to the event records (148) and other information previously recorded by the event recording component. In addition, the post-processing component (206) exports event records (148) to and imports event records (148) from external devices, such as a remote computer or medical electronic device. Finally, the post-processing component (206) generates a run report including the recorded event records (148) and information related to the incident.
A standardized treatment program of osteoporosis will be introduced successively at 7 hospitals in Norway from April 2015 to January 2016. This Project is named NoFRACT (Norwegian Capture the Fracture Initiative https://clinicaltrials.gov/show/NCT02536898). Patients above 50 years of age, who recently have suffered a fragility fracture, will be offered examination of osteoporosis and treatment if indicated. Some of these patients will be asked to participate in this consent-based sub-study (NoFRACTsub). At baseline, the patients will be asked to answer a questionnaire, collect blood-sample for to outline possible causes for osteoporosis, in addition to Dual X-Ray Apsopiometry (DXA) scan including bone mineral density(BMD), trabecular bone score(TBS) and vertebral fracture assessment (VFA). At 1-year follow-up there will be a brief questionnaire and measuring of BTM. At 2-year follow-up there will be a brief questionnaire in addition to repeated measurement of DXA including BMD, TBS and VFA. All data will be stored securly at the designated server at the University of Oslo, Service of sensitive data, TSD.
The present invention provides a new use method for anastaltic Chinese medicine. The anastaltic Chinese medicine is decocted into medicinal soup according to a recipe, and the medicinal soup is atomized into mist with particles of 2 muon m by an atomizing device. A patient uses the atomizing device to cause the medicine to continuously pass through a respiratory system and enter a patient body. The medicine enters a bronchus and a lung and reaches excretion body fluid amount of the controlled bronchial lung. Accordingly, a bronchial asthma disease can be thoroughly cured. The present invention has the advantages of simple use method, convenience and high safety and the patient has no discomfort feeling.
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. Partial hepatectomy is still considered as the conventional therapy for HCC. Intrahepatic recurrence of HCC after partial hepatectomy is common and was reported to be more than 77% within 5 years after surgery. Repeat hepatectomy is an effective treatment for intrahepaticHCC recurrence, with a 5-year survival rate of 19.4-56%. This is comparable to the survival after initial hepatectomy for HCC. Unfortunately, repeat hepatectomy could be carried out only in a small proportion of patients with HCC recurrence (10.4-31%), either because of the poor functional liver reserve or because of widespread intrahepatic recurrence. In the past two decades, percutaneous radiofrequency ablation (PRFA) has emerged as a new treatment modality and has attracted great interest because of its effectiveness and safety for small HCC (≤ 5.0 cm). Studies using PRFA to treat recurrent HCC after partial hepatectomy reported a 3-year survival rate of 62-68%, which is comparable to those achieved by surgery. PRFA is particularly suitable to treat recurrent HCC after partial hepatectomy because these tumors are usually detected when they are small and PRFA causes the least deterioration of liver function in the patients. To the best of our knowledge, there has been no report published in the medical literature comparing the efficacy of repeat hepatectomy with PRFA for recurrent HCC. The aim of this retrospective study is to compare the outcome of repeat hepatectomy with PRFA for small recurrent HCC after partial hepatectomy.
Before the taping application, the application area of all athletes will be shaved. It will be cleaned with an alcohol wipe before the application so that situations such as sweat or moisture do not reduce the effect of the banding. For taping, while the athlete lies in a supine position on a portable stretcher, the leg weight will be taken by placing the athlete's foot on the abdomen with slight knee and hip flexion. The rigid tape will be measured and cut obliquely starting approximately 2 cm anterior to the fibula and approximately 1 cm anterior to the lateral malleolus and ending in the middle of the anterior tibia region. To increase the strength of the banding, another band will be added to it. In the application, only banding will be preferred and mobilization will not be done.